5 Noteworthy Cardiovascular Studies from American Heart Month

Only 1 in 5 Women Meet Heart Health Targets at Midlife, and These 4 Factors Matter Most

News

Slideshow

Psoriasis medication for heart disease prevention, the role of artificial sweeteners in different types of stroke, and 3 other noteworthy findings from American Heart Month.

Related Content

August 4th 2025

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Adequate sleep tops the 4 elements most important to CV health after menopause, with blood pressure, glucose levels, and smoking status close behind.

Tirzepatide Proves Noninferiority With Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

August 1st 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

August 30th 2023

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

July 9th 2025

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

BF% outperforms BMI in Predicting Morality risk in young adults: New Findings / image courtesy of University of Florida

Only 1 in 5 Women Meet Heart Health Targets at Midlife, and These 4 Factors Matter Most

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

Related Content

August 4th 2025

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Adequate sleep tops the 4 elements most important to CV health after menopause, with blood pressure, glucose levels, and smoking status close behind.

Tirzepatide Proves Noninferiority With Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

August 1st 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

August 30th 2023

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

July 9th 2025

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.